Abstract:Background and objectiveCognitive impairment (CI) is a substantial contributor to the disability associated with Parkinson’s disease (PD). We aimed to assess the clinical features and explore the underlying biomarkers as predictors of CI in patients with newly diagnosed PD (NDPD; less than 2 years).MethodsWe evaluated the cognitive function status using the Montreal Cognitive Assessment (MoCA) and a battery of neuropsychological tests at baseline and subsequent annual follow-up for 5 years from the Parkinson’s Progression Markers Initiative (PPMI) database. We assessed the baseline clinical features, apolipoprotein (APO) E status, β-glucocerebrosidase (GBA) mutation status, cerebrospinal fluid findings, and dopamine transporter imaging results. Using a diagnosis of CI (combined mild cognitive impairment and dementia) developed during the 5-year follow-up as outcome measures, we assessed the predictive values of baseline clinical variables and biomarkers. We also constructed a predictive model for the diagnosis of CI using logistic regression analysis.ResultsA total of 409 patients with NDPD with 5-year follow-up were enrolled, 232 with normal cognitive function at baseline, and 94 patients developed CI during the 5-year follow-up. In multivariate analyses, age, current diagnosis of hypertension, baseline MoCA scores, Movement disorder society Unified PD Rating Scale part III (MDS-UPDRS III) scores, and APOE status were associated with the development of CI. Predictive accuracy of CI using age alone improved by the addition of clinical variables and biomarkers (current diagnosis of hypertension, baseline MoCA scores, and MDS-UPDRS III scores, APOE status; AUC 0.80 [95% CI 0.74–0.86] vs. 0.71 [0.64–0.77], p = 0.008). Cognitive domains that had higher frequencies of impairment were found in verbal memory (12.6 vs. 16.8%) and attention/processing speed (12.7 vs. 16.9%), however, no significant difference in the prevalence of CI at annual follow-up was found during the 5-year follow-up in NDPD patients.ConclusionIn NDPD, the development of CI during the 5-year follow-up can be predicted with good accuracy using a model combining age, current diagnosis of hypertension, baseline MoCA scores, MDS-UPDRS III scores, and APOE status. Our study underscores the need for the earlier identification of CI in NDPD patients in our clinical practice.

A clinical study on the cognitive impairment in patients with Parkinson's disease among natural population aged 55 years old and older

A Risk Factor Analysis of Cognitive Impairment in Elderly Patients with Chronic Diseases in a Chinese Population

The Nutritional Status of Elderly Chinese Patients with Parkinson’s Disease

Characterizing Mild Cognitive Impairment in Prodromal Parkinson’s Disease: A Community‐based Study in China

A 1:1 case- control study on neuropsychological characteristics of patients with Parkinson disease

Preliminary Study of Motor Impairment in Parkinson's Disease with Elderly Onset

[Study on the status of cognition among Parkinson's disease patients in Xi'an.].

Advanced brain aging in Parkinson’s disease with cognitive impairment

Cognitive Impairment in Patients with Parkinson's Disease: A 30-Month Follow-Up Study.

Parkinson disease-associated cognitive impairment

Predictors of Cognitive Impairment in Newly Diagnosed Parkinson’s Disease with Normal Cognition at Baseline: A 5-Year Cohort Study

Associations Between Cognitive Impairment and Motor Dysfunction in Parkinson's Disease

Predictors of cognitive impairment in Parkinson’s disease: a systematic review and meta-analysis of prospective cohort studies

Cognitive Function and Quality of Life in Parkinson's Disease: A Cross-Sectional Study

Cognitive Impairment in Parkinson's Disease Revealed by Event-Related Potential N270.

Pay attention to cognitive impairment in Parkinson′s disease

A Cross-Sectional Study of Affective, Psychiatric, Cognitive Disorders and Motor Complications of Parkinson's Disease

Evolution of Cognitive Dysfunction in an Incident Parkinson'S Disease Cohort

The Epidemiology of Parkinson Disease among Elderly People in Xi'an , China

A retrospective study of Parkinson's disease in Southwest China 2021-2024: An age-based approach

Cognitive Impairment in Parkinson’s Disease: Epidemiology, Clinical Profile, Protective and Risk Factors